Baxter wins FDA approval for renal therapy solution

SHARE Baxter wins FDA approval for renal therapy solution

A Baxter International Inc. product for use in renal replacement therapy has received approval from the U.S. Food and Drug Administration.

Baxter’s Phoxillum is designed to correct electrolyte and acid-base imbalances for patients undergoing continuous renal replacement therapy. The Deerfield pharmaceutical and medical device maker said it expects the product be available in the U.S. beginning in the second quarter.

“The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT,” said Bruce Culleton, a Baxter vice president and head of its renal therapeutic area.

The Latest
The Railsplitters avenged last season’s championship loss to Nazareth with a resounding 60-44 IHSA Class 3A state championship win over Glenwood. Froebe set a Class 3A championship scoring record with her dominant 36-point performance.
The Ramblers (38-0) came back and won the IHSA Class 4A state championship 44-40 over Nazareth, but not because of their lethal offense. They won because they got gritty on defense.
The lowly Jackets — who have won only 18 of 58 games this season against teams other than the Hawks — cruised to a 5-2 victory Saturday, outscoring the Hawks 12-5 across their two meetings this season.